Portfolio companies news

02 February 2015

NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014 - New Report Available

Global Markets Direct's, 'NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NovaDigm Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of NovaDigm Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
 

29 January 2015

Atlas Genetics completes $20m Series C fundraising

Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures and South West Ventures Fund. This newly announced financing follows on from the previously announced Series B fundraising of $25 million.

15 January 2015

Regado Biosciences and Tobira Therapeutics Announce Merger Agreement to Create Leading NASH Company

Regado Biosciences, Inc. and Tobira Therapeutics, Inc. today announced that they have entered into a definitive agreement under which privately-held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases. 

13 January 2015

LA BioMed develops promising vaccine to combat MRSA

Sandy Mazza, Daily Breeze

Grappling with one of the world’s deadliest contagions for more than a decade without a breakthrough, the country’s leading infectious disease researchers have high hopes for a vaccine developed locally.

08 January 2015

Epic Sciences Receives CLIA Certification for its Cancer Diagnostics Laboratory

Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department of Health and Human Services’ (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company’s initial CLIA clinical laboratory license.

08 January 2015

Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd. and Syndax Pharmaceuticals, Inc., today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea. Entinostat is a Class I selective histone deacetylase (HDAC) inhibitor being developed by Syndax in the United States and Europe in combination with hormone therapy for advanced breast cancer and immune therapy combinations in solid tumors.

07 January 2015

Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has retained Albena Patroneva, MD as Chief Medical Officer. Dr. Patroneva brings close to 20 years of experience spanning across research, drug development, clinical, regulatory and commercialization activities focused in neurology with large pharmaceutical companies, including AstraZeneca, Wyeth and Takeda. As Chief Medical Officer, Dr. Patroneva will oversee Marinus's clinical programs in epilepsy and pediatric orphan indications with its neurosteroid, ganaxolone.

05 January 2015

Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of macular edema associated with non-infectious uveitis using Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal (SCS) injection using Clearside’s proprietary microinjector.

11 December 2014

2-Year Study Results Point to Permanence. miraDry Long-term Results Point to Permanent Sweat Reduction

Miramar Labs®, Inc., a leading medical device manufacturer and maker of the miraDry® System, today announced the results of recently published 2-year data showing that miraDry efficacy observed at 30 days remains stable through 2 years.

11 December 2014

Vaccine May Prevent Antibiotic Resistant Skin Infections

Drud Discovery&Development

A study reported in the Proceedings of the National Academy of Sciences USA holds new hope for preventing or reducing the severity of infections caused by the “superbug” MRSA.  In the study, infectious disease specialists at the Los Angeles Biomedical Research Institute reported that a new investigational vaccine, NDV-3 (licensed to NovaDigm Therapeutics, Inc.), employing the recombinant protein Als3, can mobilize the immune system to fight off MRSA skin infections in an experimental mode.